Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis
Open Access
- 24 March 2026
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 53 (3) , 17
Abstract
Dermatomyositis (DM) is a rare and debilitating inflammatory disease associated with muscle weakness and skin manifestations. As with all rare diseases, clinical trials in DM are challenging due to the small number of patients available for study, and DM patients may even present with skin- or muscle-predominant disease. A Phase 2 study of an anti-interferon-beta monoclonal antibody (dazukibart) in DM was recently completed. Most trial data were collected in skin-predominant DM patients, measuring the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI); the Total Improvement Score (TIS) was only measured in a small subset of muscle-predominant DM patients. Because TIS is a more holistic endpoint, planning for further dazukibart development depended on a robust understanding of TIS response. This analysis aimed to develop an exposure-response model for dazukibart in DM patients. The model was intended to describe the timecourses of all relevant clinical responses, including CDASI and TIS, using the available data to collectively inform the exposure-response relationships. The model provided evidence for a TIS response in DM patients treated with dazukibart that was consistent with the observed data and supportive of further development. The model used here could be applied directly to model-based meta-analysis of other DM trials, and the general approach can be used in rare diseases with multiple endpoints. Trial registration numbers: NCT03181893, NCT02766621.Keywords
This publication has 26 references indexed in Scilit:
- Indirect modeling of derived outcomes: Are minor prediction discrepancies a cause for concern?CPT: Pharmacometrics & Systems Pharmacology, 2024
- Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo (Standard‐of‐Care) data to enable model‐informed drug developmentCPT: Pharmacometrics & Systems Pharmacology, 2022
- Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory MyositisClinical Reviews in Allergy & Immunology, 2020
- An automated sampling importance resampling procedure for estimating parameter uncertaintyJournal of Pharmacokinetics and Pharmacodynamics, 2017
- 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative InitiativeArthritis & Rheumatology, 2017
- Pharmacokinetic and Pharmacodynamic Relationship of AMG 811, An Anti-IFN-γ IgG1 Monoclonal Antibody, in Patients with Systemic Lupus ErythematosusPharmaceutical Research, 2014
- Incidence of Dermatomyositis and Clinically Amyopathic DermatomyositisArchives of Dermatology, 2010
- Approximations of the target-mediated drug disposition model and identifiability of model parametersJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patientsJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Comparison of four basic models of indirect pharmacodynamic responsesJournal of Pharmacokinetics and Biopharmaceutics, 1993